ArticleIEEE transactions on bio-medical engineering2026
High-Speed Intravascular Near-Infrared Fluorescence-Ultrasound Imaging In Vivo.
Article in IEEE transactions on bio-medical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThe combination of near-infrared fluorescence (NIRF) with intravascular ultrasound (IVUS) has shown promising applications for imaging atherosclerosis in ex vivo human arteries and in vivo animal models. However, long acquisition times, rotational distortion causing inconsistent image quality and poor catheter durability have hampered clinical translation. Technical limitations have included motor drive unit (MDU) instability, and catheter designs with a single-layer drive shaft and long rigid length of the distal tip.
methodsHerein, we present an improved, next-generation NIRF-IVUS system by integrating an aluminum v-block-based high-speed MDU and 3.0 French (∅ = 1.0 mm) catheter with a dual-layer drive shaft and reduced rigid tip length. We show a sixfold increase in imaging speed (30 FPS, 6 mm/s pullback) mirroring speed capabilities of standalone, commercial IVUS imaging.
resultsIn phantoms, we find that key NIRF-IVUS specifications like co-registration, rotational stability and NIRF resolution/sensitivity are preserved. Furthermore, we demonstrate that NIRF-IVUS molecular imaging of cathepsin protease activity can highlight stent-induced arterial inflammation independent of imaging speed, in rabbits in vivo. We calculate similar (not significant, p = 0.65) NIRF target-to-background ratios (TBRs) in stented tissue areas at low-speed (1.88) and high-speed (2.00) imaging. Finally, in vivo NIRF-IVUS imaging of FDA-approved indocyanine green detects early-stage plaques in rabbit aorta not visible on standalone IVUS. Similar NIRF TBRs are calculated in low-speed (4.13) and high-speed (4.08) pullbacks. CONCLUSION AND SIGNIFICANCE: Our study demonstrates that NIRF-IVUS can highlight key pathobiological markers of atherosclerosis beyond standalone IVUS at clinical imaging speeds, further supporting the clinical translation of the NIRF-IVUS technology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.